Recently, the Glofitamab Injection (trade name: 高罗华/Columvi) of Roche Pharma (Schweiz) AG is approved with conditions by China NMPA. This drug is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, after two or more lines of systemic therapy.

　　Glofitamab is a bispecific antibody that binds to CD20 expressed on the surface of B cells and to CD3 in the T-cell receptor complex expressed on the surface of T cells, and mediates the formation of an immunological synapses with subsequent T-cell activation and proliferation, secretion of cytokines and release of cytolytic proteins that results in the lysis of CD20-expressing B cells.

　　The marketing of this drug provides a new treatment option for adult patients with relapsed or refractory diffuse large B-cell lymphoma.